Stockscreener 앱 받기
258.73
0.73%
1.72
전일 마감가:
$257.01
열려 있는:
$256.83
하루 거래량:
244.97K
Relative Volume:
0.32
시가총액:
$18.26B
수익:
$1.98B
순이익/손실:
$420.90M
주가수익비율:
44.30
EPS:
5.84
순현금흐름:
$218.20M
1주 성능:
-0.24%
1개월 성능:
+5.56%
6개월 성능:
+7.28%
1년 성능:
+48.42%
1일 변동 폭
$252.88
$260.17
1주일 범위
$245.66
$260.17
52주 변동 폭
$160.19
$289.46
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
PODD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
259.05 | 18.26B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
132.43 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.41 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.68 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.60 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.39 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
UPC Court of Appeal reverses Milan decision in Insulet v EOFlow dispute - MLex
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Investing in Insulet (NASDAQ:PODD) a year ago would have delivered you a 47% gain - simplywall.st
Insulet Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Insulet forgoes high trade secret damages award in favour of injunction - IAM Patent
Wolfe Research Downgrades Insulet (BIT:1PODD) - Nasdaq
Insulet (PODD) Price Target Raised by Barclays Amid Leadership C - GuruFocus
Wolfe Research Downgrades Insulet (BMV:PODD) - Nasdaq
Here's What to Expect From Insulet's Next Earnings Report - MSN
Insulet stock gains on leadership change and strong outlook By Investing.com - Investing.com Canada
Canaccord maintains Buy on Insulet stock, price target at $324 - Investing.com
Insulet stock gains on leadership change and strong outlook - Investing.com
Insulet Shares Fall After Wolfe Research Downgrade - marketscreener.com
Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction - MassDevice
Hologic Adds Wayde McMillan to its Board of Directors - Medical Product Outsourcing
Canaccord maintains Buy on Insulet stock, price target at $324 By Investing.com - Investing.com India
William Blair Reiterates Outperform Rating on Insulet Corporation (PODD) - StreetInsider
This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Canaccord Genuity Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Wolfe Research Downgrades Insulet to Peer Perform From Outperform - marketscreener.com
Insulet names new CEO, plans to lift full year guidance - MSN
Insulin pump maker Insulet names J&J veteran as new CEO, replacing Hollingshead - The Business Journals
Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move - insights.citeline.com
Insulet Names New CEO, Expects to Top Revenue Projections - MSN
Insulet Appoints Ashley McEvoy as New CEO - TipRanks
Insulet (PODD) Welcomes Ashley McEvoy as New CEO, Gains Positive Outlook from Wells Fargo | PODD Stock News - GuruFocus
Insulet Earnings: What To Look For From PODD - Barchart.com
Ashley McEvoy named Insulet CEO - Yahoo Finance
Here's What To Expect From Insulet's Next Earnings Report - Barchart.com
Insulet (PODD) Appoints New CEO and Expects Revenue Surge - GuruFocus
Ashley McEvoy named president and CEO at Insulet - MassDevice
Insulet Appoints Ashley McEvoy President and CEO | PODD Stock Ne - GuruFocus
Insulet (PODD) Appoints Ashley McEvoy as New CEO | PODD Stock Ne - GuruFocus
Insulet Appoints Ashley McEvoy President And CEO - marketscreener.com
Insulet Appoints Ashley McEvoy President and CEO - Business Wire
Insulet's $452M Trade Secrets Award Reduced To $59.4M - Law360
Insulet Wins Worldwide Trade Secrets Injunction, Award Slashed - Bloomberg Law News
Automated Insulin Delivery System Market Is Booming Worldwide - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Insulet Corp (PODD) Stock Price Up 5.81% on Apr 24 - GuruFocus
Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Insulet Corp. stock rises Wednesday, still underperforms market - MarketWatch
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today - Benzinga
Insulet Corp (PODD) Shares Up 3.14% on Apr 22 - GuruFocus
Study Data Show Significant Glycemic Improvements With Omnipod 5 - Medical Product Outsourcing
RBC Cuts Price Target on Insulet to $325 From $340, Keeps Outperform Rating - marketscreener.com
What's Driving the Market Sentiment Around Insulet? - Benzinga
Insulet Announces Proposal for Upcoming Financing Deals - The Healthcare Technology Report.
Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insider Sell: Insulet - marketscreener.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.59%
0.04%
자본화:
|
볼륨(24시간):